RNA interference (RNAi) specialist Dicerna Pharmaceuticals (Nasdaq: DRNA) is to be acquired by Danish diabetes giant Novo Nordisk (NOV: N) for about $3.3 billion.
The purchase of Dicerna’s proprietary “GalXC” RNAi platform represents a logical next step in the firm’s strategy of increasing investments in diverse technologies which augment its R&D capabilities.
Novo and Dicerna have been engaged since 2019 in an ongoing collaboration to discover and develop novel therapies for liver-related cardio-metabolic diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze